Evidence that new anti hypertensives are superior to older drugs

被引：45

作者：

Staessen, JA ^{[1
]}

Birkenhäger, WH ^{[1
]}

机构：

[1] Univ Louvain, Study Coordinating Ctr, Hypertens Unit, B-3000 Louvain, Belgium

来源：

LANCET | 2005年 / 366卷 / 9489期

关键词：

D O I：

10.1016/S0140-6736(05)67147-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：869 / 871

页数：3

共 18 条

[1] Diuretic versus α-blocker as first-step antihypertensive therapy -: Final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [J].

Alderman, MH .

HYPERTENSION, 2003, 42 (03) :239-246

[2]

Braunwald E, 2004, NEW ENGL J MED, V351, P2058

[3] Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].

Brown, MJ ;

Palmer, CR ;

Castaigne, A ;

de Leeuw, PW ;

Mancia, G ;

Rosenthal, T ;

Ruilope, LM .

LANCET, 2000, 356 (9227) :366-372

[4] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].

Dahlöf, B ;

Sever, PS ;

Poulter, NR ;

Wedel, H ;

Beevers, DG ;

Caulfield, M ;

Collins, R ;

Kjeldsen, SE ;

Kristinsson, A ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Östergren, J .

LANCET, 2005, 366 (9489) :895-906

[5]

Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981

[6] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial [J].

Julius, S ;

Kjeldsen, SE ;

Weber, M ;

Brunner, HR ;

Ekman, S ;

Hansson, L ;

Hua, TS ;

Laragh, J ;

McInnes, GT ;

Mitchell, L ;

Plat, F ;

Schork, A ;

Smith, B ;

Zanchetti, A .

LANCET, 2004, 363 (9426) :2022-2031

[7] 2003 European society of hypertension -: European Society of Cardiology guidelines for the management of arterial hypertension [J].

Mancia, G ;

Rosei, EA ;

Cifkova, R ;

DeBacker, G ;

Erdine, S ;

Fagard, R ;

Farsang, C ;

Heagerty, AM ;

Kawecka-Jaszcs, K ;

Kiowski, W ;

Kjeldsen, S ;

Lüscher, T ;

McInnes, G ;

Mallion, JM ;

Brien, EO ;

Poulter, NR ;

Priori, SG ;

Rahn, KH ;

Rodicio, JL ;

Ruilope, LM ;

Safar, M ;

Staessen, JA ;

van Zwieten, P ;

Waeber, B ;

Williams, B ;

Zanchetti, A ;

Zannad, F .

JOURNAL OF HYPERTENSION, 2003, 21 (06) :1011-1053

[8] Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) [J].

Poulter, NR ;

Wedel, H ;

Dahlöf, B ;

Sever, PS ;

Beevers, DG ;

Caulfield, M ;

Kjeldsen, SE ;

Kristinsson, A ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Östergren, J ;

Pocock, S .

LANCET, 2005, 366 (9489) :907-913

[9] Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial [J].

Sever, PS ;

Dahlöf, B ;

Poulter, NR ;

Wedel, H ;

Beevers, G ;

Caulfield, M ;

Collins, R ;

Kjeldsen, SE ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Ostergren, J .

JOURNAL OF HYPERTENSION, 2001, 19 (06) :1139-1147

[10] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial [J].

Sever, PS ;

Dahlöf, B ;

Poulter, NR ;

Wedel, H ;

Beevers, G ;

Caulfield, M ;

Collins, R ;

Kjeldsen, SE ;

Kristinsson, A ;

McInnes, GT ;

Mehlsen, J ;

Nieminen, M ;

O'Brien, E ;

Östergren, J .

LANCET, 2003, 361 (9364) :1149-1158

← 1 2 →